Regenxbio Slump: Spine Nodules Halt Therapy Trial

Regenxbio (RGNX) shares plunged roughly 22% on Monday after regulators imposed a clinical hold on RGX-121, the company’s investigational gene therapy for Hunter syndrome, following the discovery of nodules and masses on patients’ spines. The finding marks the second Regenxbio program paused by regulators in recent months, raising broader questions about the safety profile of […]